UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)
A turning point for pancreatic cancer patients
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
A standing ovation for RevMed, and caution for Akeso
Mercy BioAnalytics to Present Data at ASCO Evaluating Clinical Performance of a Blood-Based Lung Cancer Early Detection Assay in Biospecimens from the National Lung Screening Trial
'Immediately Practice-Changing' Lung Cancer Trial in Curative Setting
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by…
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3…
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already
